&Partners’s FibroBiologics FBLG Stock Holding History

&Partners’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,000	Closed	-$22.5K	–	2478
2025 Q4	$22.5K	Hold	5,000	–	–	﹤0.01%	2263
2025 Q3	$54.6K	Buy	5,000 +1,500	+43%	+$18K	﹤0.01%	2075
2025 Q2	$43.6K	Buy	+3,500	New	+$63.1K	﹤0.01%	1954

Other funds holding FBLG

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FEG

Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

VGA

Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

&Partners's FBLG Position: Q1 2026 in Review

&Partners sold out of FibroBiologics (FBLG) in Q1 2026, closing a stake of 5,000 shares — an estimated $22.5K sold.

&Partners first reported a position in FBLG in Q2 2025 and held it in 3 quarters. The position peaked at $54.6K in Q3 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

&Partners reported no remaining FibroBiologics position as of Q1 2026 after selling out during the quarter.
&Partners sold 5,000 FibroBiologics shares in Q1 2026, an estimated $22.5K.
&Partners first reported a position in FibroBiologics in Q2 2025 and held it in 3 quarters.
&Partners's FibroBiologics position peaked at $54.6K in Q3 2025.
17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.